Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B
Objectives. We assessed the potential of glial cell line-derived neurotrophic factor (GDNF) as a useful biomarker to predict cirrhosis in chronic hepatitis B (CHB) patients. Methods. A total of 735 patients from two medical centers (385 CHB patients and 350 healthy controls) were included to determi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2022/1048104 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558366097932288 |
|---|---|
| author | Guangyue Yang Liping Zhuang Tiantian Sun Yee Hui Yeo Le Tao Wei Zhang Wenting Ma Liu Wu Zongguo Yang Yanqin Yang Dongying Xue Jie Zhang Rilu Feng Ebert Matthias P. Steven Dooley Ekihiro Seki Ping Liu Cheng Liu |
| author_facet | Guangyue Yang Liping Zhuang Tiantian Sun Yee Hui Yeo Le Tao Wei Zhang Wenting Ma Liu Wu Zongguo Yang Yanqin Yang Dongying Xue Jie Zhang Rilu Feng Ebert Matthias P. Steven Dooley Ekihiro Seki Ping Liu Cheng Liu |
| author_sort | Guangyue Yang |
| collection | DOAJ |
| description | Objectives. We assessed the potential of glial cell line-derived neurotrophic factor (GDNF) as a useful biomarker to predict cirrhosis in chronic hepatitis B (CHB) patients. Methods. A total of 735 patients from two medical centers (385 CHB patients and 350 healthy controls) were included to determine the association of serum and tissue GDNF levels with biopsy-proven cirrhosis. The diagnostic accuracy of serum GDNF (sGDNF) was estimated and compared with other indices of cirrhosis. Results. We showed significantly higher levels of sGDNF in CHB patients with fibrosis (28.4 pg/ml vs. 11.6 pg/ml in patients without) and patients with cirrhosis (33.8 pg/ml vs. 23.5 pg/ml in patients without). The areas under receiver operating curve (AUROCs) of sGDNF were 0.83 (95% confidence interval (CI): 0.80–0.87) for predicting liver fibrosis and 0.84 (95% CI: 0.79–0.89) for cirrhosis. Findings from the serum protein level and hepatic mRNA expression were consistent. Using the best cutoff to predict cirrhosis, we categorized the patients into sGDNF-high and sGDNF-low groups. The sGDNF-high group had significantly larger Masson’s trichrome and reticulin staining-positive area, higher Scheuer score, and METAVIR fibrosis stage (all p<0.001) but not steatosis. On multivariable regression, sGDNF was independently associated with cirrhosis with an odds ratio of 6.98 (95% CI: 1.10–17.94). Finally, we demonstrated that sGDNF outperformed AST to platelet ratio index, FIB-4, fibroscore, forn index, and fibrometer in differentiating F4 vs. F3. Conclusion. Using serum, tissue mRNA, and biopsy data, our study revealed a significant potential of sGDNF as a novel noninvasive biomarker for cirrhosis in CHB patients. |
| format | Article |
| id | doaj-art-10add78985e142b39a5c8c2ff4f22221 |
| institution | Kabale University |
| issn | 2291-2797 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-10add78985e142b39a5c8c2ff4f222212025-02-03T01:32:29ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/1048104Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis BGuangyue Yang0Liping Zhuang1Tiantian Sun2Yee Hui Yeo3Le Tao4Wei Zhang5Wenting Ma6Liu Wu7Zongguo Yang8Yanqin Yang9Dongying Xue10Jie Zhang11Rilu Feng12Ebert Matthias P.13Steven Dooley14Ekihiro Seki15Ping Liu16Cheng Liu17Laboratory of Liver DiseaseDepartment of Integrative OncologyLaboratory of Liver DiseaseDivision of General Internal MedicineLaboratory of Liver DiseaseLaboratory of Liver DiseaseLaboratory of Liver DiseaseLaboratory of Liver DiseaseDepartment of Integrative MedicineDepartment of PathologyLaboratory of Liver DiseaseLaboratory of Liver DiseaseDepartment of Medicine IIDepartment of Medicine IIDepartment of Medicine IIDivision of Digestive and Liver DiseasesInstitute of Liver DiseasesLaboratory of Liver DiseaseObjectives. We assessed the potential of glial cell line-derived neurotrophic factor (GDNF) as a useful biomarker to predict cirrhosis in chronic hepatitis B (CHB) patients. Methods. A total of 735 patients from two medical centers (385 CHB patients and 350 healthy controls) were included to determine the association of serum and tissue GDNF levels with biopsy-proven cirrhosis. The diagnostic accuracy of serum GDNF (sGDNF) was estimated and compared with other indices of cirrhosis. Results. We showed significantly higher levels of sGDNF in CHB patients with fibrosis (28.4 pg/ml vs. 11.6 pg/ml in patients without) and patients with cirrhosis (33.8 pg/ml vs. 23.5 pg/ml in patients without). The areas under receiver operating curve (AUROCs) of sGDNF were 0.83 (95% confidence interval (CI): 0.80–0.87) for predicting liver fibrosis and 0.84 (95% CI: 0.79–0.89) for cirrhosis. Findings from the serum protein level and hepatic mRNA expression were consistent. Using the best cutoff to predict cirrhosis, we categorized the patients into sGDNF-high and sGDNF-low groups. The sGDNF-high group had significantly larger Masson’s trichrome and reticulin staining-positive area, higher Scheuer score, and METAVIR fibrosis stage (all p<0.001) but not steatosis. On multivariable regression, sGDNF was independently associated with cirrhosis with an odds ratio of 6.98 (95% CI: 1.10–17.94). Finally, we demonstrated that sGDNF outperformed AST to platelet ratio index, FIB-4, fibroscore, forn index, and fibrometer in differentiating F4 vs. F3. Conclusion. Using serum, tissue mRNA, and biopsy data, our study revealed a significant potential of sGDNF as a novel noninvasive biomarker for cirrhosis in CHB patients.http://dx.doi.org/10.1155/2022/1048104 |
| spellingShingle | Guangyue Yang Liping Zhuang Tiantian Sun Yee Hui Yeo Le Tao Wei Zhang Wenting Ma Liu Wu Zongguo Yang Yanqin Yang Dongying Xue Jie Zhang Rilu Feng Ebert Matthias P. Steven Dooley Ekihiro Seki Ping Liu Cheng Liu Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B Canadian Journal of Gastroenterology and Hepatology |
| title | Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B |
| title_full | Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B |
| title_fullStr | Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B |
| title_full_unstemmed | Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B |
| title_short | Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B |
| title_sort | serum glial cell line derived neurotrophic factor sgdnf is a novel biomarker in predicting cirrhosis in patients with chronic hepatitis b |
| url | http://dx.doi.org/10.1155/2022/1048104 |
| work_keys_str_mv | AT guangyueyang serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT lipingzhuang serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT tiantiansun serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT yeehuiyeo serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT letao serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT weizhang serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT wentingma serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT liuwu serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT zongguoyang serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT yanqinyang serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT dongyingxue serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT jiezhang serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT rilufeng serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT ebertmatthiasp serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT stevendooley serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT ekihiroseki serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT pingliu serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb AT chengliu serumglialcelllinederivedneurotrophicfactorsgdnfisanovelbiomarkerinpredictingcirrhosisinpatientswithchronichepatitisb |